News Releases

January 2020

January 14, 2020 1/14/2020 Takeda To Outline Progress on Business Transformation and Priorities at the 38th Annual J.P. Morgan Healthcare Conference

January 8, 2020 1/8/2020 Takeda to Present at the 38th Annual J.P. Morgan Healthcare Conference

December 2019

December 20, 2019 12/20/2019 Takeda Receives Complete Response Letter from U.S. FDA for the Investigational Subcutaneous Formulation of ENTYVIO® (vedolizumab) as a Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis

December 16, 2019 12/16/2019 TAKEDA ANNOUNCES EXPIRATION AND RESULTS OF EXCHANGE

December 9, 2019 12/9/2019 Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting

December 9, 2019 12/9/2019 Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019

December 7, 2019 12/7/2019 Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis

November 2019

November 23, 2019 11/23/2019 Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene (ASTMH) 68th Annual Meeting

November 23, 2019 11/23/2019 Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up

・For legacy Shire information, click here